HUT54037A - Process for producing retarde compositions containing water-soluble peptides - Google Patents

Process for producing retarde compositions containing water-soluble peptides

Info

Publication number
HUT54037A
HUT54037A HU903974A HU397490A HUT54037A HU T54037 A HUT54037 A HU T54037A HU 903974 A HU903974 A HU 903974A HU 397490 A HU397490 A HU 397490A HU T54037 A HUT54037 A HU T54037A
Authority
HU
Hungary
Prior art keywords
retarde
producing
compositions containing
containing water
soluble peptides
Prior art date
Application number
HU903974A
Other languages
Hungarian (hu)
Other versions
HU221294B1 (en
HU903974D0 (en
Inventor
David Bodmer
Jones Wing Fong
Thomas Kissel
Hawkins Valliant Maulding
Oskar Nagele
Jane Edna Pearson
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to HU9700678A priority Critical patent/HU217117B/en
Publication of HU903974D0 publication Critical patent/HU903974D0/en
Priority to US07/643,880 priority patent/US5538739A/en
Publication of HUT54037A publication Critical patent/HUT54037A/en
Priority to PH41987A priority patent/PH30995A/en
Priority to US08/470,907 priority patent/US5876761A/en
Priority to US08/470,072 priority patent/US5639480A/en
Priority to US08/470,909 priority patent/US5688530A/en
Publication of HU221294B1 publication Critical patent/HU221294B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU974/90A 1989-07-07 1990-06-25 Process for producing retarde compositions containing the active ingredient in a polymeric carrier HU221294B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
HU9700678A HU217117B (en) 1989-09-22 1990-06-25 Process for producing oktreotide pamoate
US07/643,880 US5538739A (en) 1989-07-07 1991-01-18 Sustained release formulations of water soluble peptides
PH41987A PH30995A (en) 1989-07-07 1991-02-13 Sustained release formulations of water soluble peptides.
US08/470,907 US5876761A (en) 1989-07-07 1995-06-06 Sustained release formulations of water soluble peptides
US08/470,072 US5639480A (en) 1989-07-07 1995-06-06 Sustained release formulations of water soluble peptides
US08/470,909 US5688530A (en) 1989-07-07 1995-06-06 Sustained release formulations of water soluble peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (3)

Publication Number Publication Date
HU903974D0 HU903974D0 (en) 1990-11-28
HUT54037A true HUT54037A (en) 1991-01-28
HU221294B1 HU221294B1 (en) 2002-09-28

Family

ID=27007654

Family Applications (2)

Application Number Title Priority Date Filing Date
HU974/90A HU221294B1 (en) 1989-07-07 1990-06-25 Process for producing retarde compositions containing the active ingredient in a polymeric carrier
HU95P/P00523P HU211602A9 (en) 1989-07-07 1995-06-28 Sustained release formulations of water soluble peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU95P/P00523P HU211602A9 (en) 1989-07-07 1995-06-28 Sustained release formulations of water soluble peptides

Country Status (27)

Country Link
JP (5) JPH0832624B2 (en)
KR (2) KR100303681B1 (en)
AT (1) AT406225B (en)
AU (2) AU641407B2 (en)
BE (1) BE1004486A3 (en)
CA (1) CA2020477C (en)
CH (1) CH685230A5 (en)
CY (1) CY1965A (en)
DE (2) DE4042752B4 (en)
DK (1) DK175849B1 (en)
FI (3) FI108611B (en)
FR (1) FR2649319A1 (en)
GB (2) GB2234896B (en)
GR (1) GR1001121B (en)
HK (2) HK97695A (en)
HU (2) HU221294B1 (en)
IE (2) IE64411B1 (en)
IL (3) IL94983A (en)
IT (1) IT1241460B (en)
LU (1) LU87764A1 (en)
MY (1) MY106722A (en)
NL (1) NL195027C (en)
NO (2) NO302928B1 (en)
NZ (1) NZ234384A (en)
PT (1) PT94628B (en)
SE (1) SE512992C2 (en)
SG (1) SG26416G (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (en) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft PROCEDURE FOR OBTAINING BIOLOGICAL DEGRADABLE MICROPARTICLES WITH LONG TERM ACTION
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
DE4218510A1 (en) * 1992-06-02 1993-12-09 Pharmatech Gmbh Process for the preparation of biodegradable polyesters
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
JP2944419B2 (en) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト Stability of pharmacologically active ingredients in sustained release compositions
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
ATE288270T1 (en) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv MICRO-ENCAPSULED 1,2-BENZAZOLE
WO1997017063A1 (en) 1995-11-09 1997-05-15 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (en) * 2000-06-28 2003-07-22 동국제약 주식회사 Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7252842B2 (en) 2000-12-21 2007-08-07 Alrise Biosystems Gmbh Induced phase transition method for the production of microparticles containing hydrophilic active agents
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (en) * 2003-06-24 2005-06-09 Novartis Ag PHARMACEUTICAL COMPOSITION INCLUDING CYCLIC ANALOGS OF SOMATOSTATIN
JP2008518881A (en) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． Prevention of molecular weight reduction, impurity formation and gelation of polymer in polymer composition
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
US20070259047A1 (en) * 2004-02-26 2007-11-08 Yasuaki Ogawa Protein Sustained-Release Microparticle Preparation for Injection and Process for Producing the Same
DE102004053373A1 (en) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Invention relating to nano / meso-fiber anisometric particles in the form of nano / meso-fiber tubes, cables and their curved or branched modifications
KR100741867B1 (en) * 2005-07-05 2007-07-24 전북대학교산학협력단 Method of Preparation of Double Layered Microspheres Using Oil-in-water and Solvent Evaporation
RU2464972C2 (en) * 2005-12-22 2012-10-27 Новартис Аг Composition with delayed release, including octreotide and two or more polylactide and glycolide copolymers
KR100816065B1 (en) * 2006-11-27 2008-03-24 동국제약 주식회사 Method for preparing sustained release microcapsules with excellent initial release control characteristics and microcapsules prepared by the same
EP2247282B1 (en) 2008-01-30 2014-08-20 Novartis AG Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN103370057A (en) * 2010-09-30 2013-10-23 赢创有限公司 Method for removing residual organic solvent from microparticles
WO2012044675A2 (en) * 2010-09-30 2012-04-05 Surmodics Pharmaceuticals, Inc. Emulsion method for preparing low residual solvent microparticles
TW201605488A (en) 2013-10-15 2016-02-16 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease
KR102464650B1 (en) 2016-05-03 2022-11-10 엘에스일렉트릭(주) Current limiting device of circuit breaker
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (en) 2016-08-31 2019-07-05 Mapi医药公司 Depot system containing glatiramer acetate
BR112019017724A2 (en) 2017-03-26 2020-03-31 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS TO TREAT PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (en) * 1977-08-25 1985-05-15 Sandoz Ag BROMOCRIPTIN CONTAINING MICROCAPSULES.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE3062075D1 (en) * 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CH656884A5 (en) * 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (en) * 1985-04-11 1994-08-03 住友製薬株式会社 Sustained release formulation
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (en) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd Preparation of sustained release preparation
CH660302A5 (en) * 1984-10-17 1987-04-15 Debiopharm Sa HETEROGENEOUS PHASE MICRO-ENCAPSULATION PROCESS OF WATER-SOLUBLE DRUG SUBSTANCES.
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (en) * 1986-03-06 1996-10-02 日本原子力研究所 Process for producing sustained-release drug complex composed of polylactone
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (en) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (en) * 1987-11-11 1989-05-24 Hoechst Ag METHOD FOR PRODUCING BIODEGRADABLE MICRO-CAPSULES OF WATER-SOLUBLE PEPTIDES AND PROTEINS AND MICRO-CAPSULES OBTAINED BY THIS PROCESS
JP2653255B2 (en) * 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules

Also Published As

Publication number Publication date
IE64216B1 (en) 1995-07-26
NL195027B (en) 2003-08-01
DE4021517B4 (en) 2009-04-09
IE64411B1 (en) 1995-08-09
IL94983A (en) 1999-08-17
GR1001121B (en) 1993-04-28
NL195027C (en) 2003-12-02
NO903001D0 (en) 1990-07-05
JPH07285853A (en) 1995-10-31
CA2020477A1 (en) 1991-01-08
CY1965A (en) 1997-07-04
CH685230A5 (en) 1995-05-15
DK175849B1 (en) 2005-03-29
AU5874690A (en) 1991-01-10
GR900100513A (en) 1991-12-10
JPH0368511A (en) 1991-03-25
FI20000060L (en) 2000-01-12
FR2649319B1 (en) 1994-12-09
KR100442931B1 (en) 2004-08-02
MY106722A (en) 1995-07-31
LU87764A1 (en) 1992-03-11
IE902435A1 (en) 1991-02-13
IT9048113A0 (en) 1990-07-05
AU687553B2 (en) 1998-02-26
DE4021517A1 (en) 1991-01-17
PT94628B (en) 1997-06-30
NO903001L (en) 1991-01-08
GB9014704D0 (en) 1990-08-22
HU221294B1 (en) 2002-09-28
CA2020477C (en) 2000-11-21
SE9002364D0 (en) 1990-07-05
GB2265311B (en) 1994-02-09
HU211602A9 (en) 1995-12-28
GB2265311A (en) 1993-09-29
HU903974D0 (en) 1990-11-28
BE1004486A3 (en) 1992-12-01
NO983923L (en) 1991-01-08
AT406225B (en) 2000-03-27
ATA144090A (en) 1999-08-15
DK162590A (en) 1991-01-08
NL9001537A (en) 1991-02-01
IL131881A (en) 2001-12-23
FI109543B (en) 2002-08-30
GB2234896B (en) 1994-01-19
GB2234896A (en) 1991-02-20
JPH0832624B2 (en) 1996-03-29
SG26416G (en) 1995-09-01
IT9048113A1 (en) 1992-01-05
JPH07309897A (en) 1995-11-28
KR910002430A (en) 1991-02-25
FR2649319A1 (en) 1991-01-11
JP2001233897A (en) 2001-08-28
NO983923D0 (en) 1998-08-26
JPH08198771A (en) 1996-08-06
FI109334B (en) 2002-07-15
FI20000059L (en) 2000-01-12
NO302928B1 (en) 1998-05-11
FI903429A0 (en) 1990-07-06
IL94983A0 (en) 1991-06-10
SE512992C2 (en) 2000-06-12
NO320444B1 (en) 2005-12-05
JP2931773B2 (en) 1999-08-09
PT94628A (en) 1991-03-20
DK162590D0 (en) 1990-07-05
FI108611B (en) 2002-02-28
AU2332195A (en) 1995-09-07
KR100303681B1 (en) 2002-05-16
HK97695A (en) 1995-06-23
NZ234384A (en) 1994-05-26
DE4042752B4 (en) 2009-05-07
GB9306204D0 (en) 1993-05-19
SE9002364L (en) 1991-01-08
AU641407B2 (en) 1993-09-23
IT1241460B (en) 1994-01-17
IL131880A (en) 2001-12-23
HK197496A (en) 1996-11-08

Similar Documents

Publication Publication Date Title
HUT46232A (en) Process for producing compositions containing peptides
HUT54386A (en) Process for producing renin-inhibitor peptides and pharmaceutical compositions containing them
GB8810193D0 (en) Detergent compositions & process for preparing them
GB8817386D0 (en) Detergent compositions & process for preparing them
GB8922018D0 (en) Detergent compositions and process for preparing them
GB8907187D0 (en) Detergent compositions and process for preparing them
HUT54046A (en) Process for producing pharmaceutical compositions
GB8810821D0 (en) Detergent compositions & process for preparing them
HUT58304A (en) Process for producing quinazolin-3-alkane-acids and pharmaceutical compositions containing them
AU4987590A (en) Process for the preparation of semi-aromatic polyamides
PH25538A (en) Process for preparing detergent compositions
YU67290A (en) Process for preparing cephodizim-disodium
HU906358D0 (en) Process for producing nukleosides and pharmaceutical compositions containing them
GB8822456D0 (en) Detergent compositions & processes for preparing them
EP0456838A4 (en) Process for producing glycine
IL96090A0 (en) Diazabicycloamine compounds,a process for their preparation and compositions containing them
GB8815669D0 (en) Aerated compositions & process for making them
HUT58528A (en) Process for producing compositions against retrovirus
HUT54296A (en) Process for producing and utilizing fibre-conditioning compositions containing solved poly-lower-alkylene compound
GR900100491A (en) Acaricidel compositions and process for preparing same
HUT56264A (en) Process for producing pharmaceutical compositions for external application
HU908029D0 (en) Process for hand-made packing
GB9015680D0 (en) Process
HUT55636A (en) Process for producing pharmaceutical composition
HU900036D0 (en) Process for preparation of 2,4-diamino-6-pyperidinyl-pyrimidin-3-n-oxide

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: NOVARTIS AG., CH